Troubadour Resources Announces Non-Brokered Private Placement
Rescue Financing at All-Time Lows Following Exploration Wipeout

The most recent news (February 18, 2026) announces a non-brokered private placement to raise up to $3,600,000. The financing is split into a $3.0M "Hard Dollar" tranche at $0.02 per unit (including a warrant at $0.025) and a $600,000 "Flow-Through" (FT) tranche at $0.025 per unit (including a warrant at $0.025). This follows the February 13, 2026, announcement that Phase 1 drilling at the flagship Senneville property returned "no significant results" despite previous news releases (January 30, 2026) touting "target mineralization intercepts."
The impact is heavily negative for existing shareholders. - Massive Dilution: The company plans to issue up to 174,000,000 new shares (150M hard, 24M FT). Based on the 70,068,574 shares outstanding as of September 2025, this represents a potential dilution of approximately 248%. - Value Destruction: The financing price of $0.02 is a 90.5% discount to the $0.21 financing price closed in August 2024. - Strategic Failure: The capital is being raised at all-time lows because the Phase 1 drill program failed to validate the Gustav Cere target. The company is essentially resetting its valuation to a "shell-like" level to stay solvent. - Misleading Narrative: Management’s January 30 report of "intercepting mineralization" over long widths (up to 57.8m) appears to have been a promotion that failed to deliver any economic grade, evidenced by the February 13 assay results.
Troubadour Resources is a Vancouver-based explorer focused on the Senneville Gold-Silver-Copper Project in the Abitibi Greenstone Belt, Quebec. - Flagship Project: Senneville Project (100% option). - Development Stage: Early-stage exploration. - Recent Activity: Completed 1,000m (7 holes) of a planned 10,000m program. The program focused on the Gustav Cere showing but failed to show continuity of mineralization. - Status: The project is now in a "re-evaluation" phase after the primary high-grade targets failed to produce significant assays.